← back to ranking

ALHC · Alignment Healthcare, Inc.

Medical - Healthcare Plans · mkt cap $3.2B · calls: Q1 FY2026 vs Q4 FY2025
36.0 conviction · conf-adj 36

conf 6/10

enthusiasm:18.0 · trend:-5 · quantifies:5 · impact:0 · under_radar:14 · credibility:0 · business_impact:4 · disruption:0 · confirmation:0

Enthusiasm latest 6 / prev 7 (falling)

ALHC's AI thesis centers on its AIVA/AVA platform for risk stratification plus a 30+-use-case agentic AI pipeline targeting administrative automation (claims processing, contract management, member services) and clinical precision, with SG&A and MLR compression as the primary financial levers. The only hard quantification is claims auto adjudication jumping from <15% to >60% in 12 months, though management never explicitly labels this as AI-driven, and a 60-bp SG&A improvement is attributed only partly to 'back-office automation.' Credibility is limited by a two-quarter pattern of describing foundational prerequisites rather than live AI outcomes, culminating in Q1 FY2026 with an explicit deferral of AI disclosure to the following call — suggesting the agentic pipeline remains largely pre-deployment.

GROUNDED NEXT-FY IMPACT vs CONSENSUS

Grounded on actual base — revenue $3.9B · net income $-0.0B · net margin -0.0% · diluted EPS -0.0037

These are next-fiscal-year annual uplift estimates, not next-quarter numbers.

Aggregate next-FY est. rev uplift: 0.0% · next-FY EPS uplift: % · vs analysts: inline · priced in: low (model's call-read: medium; verdict above is the hard-data one used for ranking) · confidence: 6/10

ClaimFigureArithmeticNext-FY Rev %Next-FY EPS %
Claims auto-adjudication <15% to >60% YTD
productivity · soft		<15% to >60% auto-adjudication (12 mo. to Q1 2026)Disclosed rate change only (45+ pp automation); no $ claims-processing cost, volume, or $/claim savings in inputs → cannot compute $ or % of revenue/EPS without inventing a base.
Adjusted SG&A ratio −60 bps YoY (9.4%→8.7% of revenue)
cost		60 bps of revenue (Q1 2026 vs Q1 2025)DISCLOSED ratio: 0.0060 × FY2026 consensus revenue $5,185,589,083 = $31,113,534 pretax opex save; ×(1−21% tax) = $24,579,692 after-tax. Vs FY2025 revenue: $31,113,534 / $3,948,719,000 = 0.788% (revenue-scale magnitude); vs FY2026 revenue: exactly 0.60%. Topline uplift = 0 (cost-only). EPS% vs GAAP NI ($−724k) suppressed → null per loss-making guardrail; vs 2026 consensus NI $42,356,670 = 58.0% of consensus NI (upper bound—management cites automation only as partial driver).0
FY2026 AI/tech CapEx ~$40M
other		~$40 million (FY2026)$40,000,000 / $3,948,719,000 revenue = 1.013% of FY2025 revenue (investment intensity, not revenue uplift). P&L drag if capitalized & straight-line amortized over 5 years: $8,000,000/yr pretax D&A; ×0.79 = $6,320,000/yr after-tax earnings headwind. Net vs SG&A save above: $24,579,692 − $6,320,000 = $18,259,692 after-tax (43.1% of 2026 consensus NI)—phasing/amortization life assumed.0

Assumptions: Adopter-side MA insurer only. SG&A: full 60 bps applied to FY2026 consensus revenue $5,185,589,083 as next-FY run-rate (Q1 2026 ratio held for full year; Q1 revenue ≈ ¼×FY26 → same $31.1M). Cost saves: 21% tax; rev_uplift_pct = 0 for opex items. CapEx: $40M in FY2026, 5-year straight-line amortization (sensitivity: 3-yr → $10.0M pretax drag). Incremental margin on revenue: N/A (no revenue claims). EPS uplift vs GAAP FY2025 NI ($−724k) not computed (meaningless denominator); vs consensus 2026 adjusted EPS $0.18423 implied +67.4% on earnings dollars but est_eps_uplift_pct left null per guardrail. AI attribution haircut NOT applied to 60 bps (total SG&A improvement; quote attributes only part to back-office automation).

Top line: No quantified AI revenue/bookings claims. Aggregate adopter revenue uplift = 0%. Hard productivity metric (claims auto-adjudication) has no $ anchor. FY2026 $40M CapEx is 1.01% of FY2025 revenue—balance-sheet/opex investment, not topline.

Bottom line: Only hard P&L lever: 60 bps adjusted SG&A on FY2026 revenue = $31.1M pretax ($24.6M after-tax), 0.79% of FY2025 revenue / 0.60% of FY2026 revenue—166% of FY2025 operating income ($14.8M), illustrating thin-margin denominator risk. Offset: ~$6.3M after-tax annual D&A from $40M CapEx (5-yr life) → net ~$18.3M after-tax (~43% of 2026 consensus NI $42.4M). GAAP EPS-uplift % vs FY2025 NI not reported (loss-making base).

[EPS uplift n/m (loss-making base)] Consensus FY2025→FY2026: revenue +31.6% ($3.94B→$5.19B), EPS −$0.102→+$0.184, NI swing +$64.3M (−$21.9M→+$42.4M). Quantified adopter opex save ($24.6M after-tax, upper bound) equals 38.2% of that NI swing and 58.0% of level FY2026 NI—material but not majority of inflection, and management does not attribute all 60 bps to AI. Forward agentic-AI/member-services/MLR claims unquantified. Net of CapEx amortization (~$18.3M) still ~43% of FY2026 consensus NI—likely partially embedded in margin expansion already assumed by 6 analysts; not clearly above consensus on revenue (0% quantified uplift).

QUANTIFICATIONS
Claims auto adjudication rate: From <15% to >60% YTD (12-month period ending Q1 2026, bottomline)
“just 12 months ago, our claims auto adjudication rate was less than 15%. Now our year-to-date auto adjudication rate is over 60%, and we expect to drive even higher claims automation as we progress throughout this year.”
Adjusted SG&A ratio improvement (partially attributed to back-office automation): 60 basis points year-over-year (9.4% → 8.7% of revenue) (Q1 2026 vs. Q1 2025, bottomline)
“Our SG&A discipline and scalability initiatives such as back-office automation supported outperformance in our operating cost ratio. ... Adjusted SG&A as a percentage of revenue declined from 9.4% in the first quarter of 2025 to 8.7% in the first quarter of 2026.”
CapEx directed toward AI/technology infrastructure (workflow documentation and AI tool deployment): ~$40 million (Full year 2026, bottomline)
“this year, we are probably in the $40 million spend range... And that is where the CapEx is going towards. [in context of end-to-end workflow documentation to enable AI tool application]”
PAST (realized)
CURRENT (now)
FORWARD (guidance)
PRICED-IN (REFINED)
LOW (room left)

Est. revisions falling  ·  Fwd P/E -149.6  ·  EV/Sales 0.5x

AI claim maps to Health Care Capitation, Health Care, Premium

Estimate-revision momentum is weak to negative: price targets stepped down from ~$22 (last year) to ~$19.75 (last quarter) to ~$19 (last month), while rating counts only nudged from 9 to 10 Buys with Holds flat—not a rising-revision setup. Valuation is not stretched on sales (EV/Sales ~0.5x, P/S ~0.74x); next-FY consensus EPS is still negative so forward P/E is not meaningful, though TTM P/E is high on thin earnings. AI-driven medical-cost, care-management, and admin efficiency would most plausibly affect capitated VBC economics and scale in the premium line, not a separate AI revenue bucket. Falling/flat revisions plus modest revenue multiples leave room for AI upside to re-rate estimates rather than reflect work already done in the price.
BUSINESS IMPACT - QUALITATIVE MATERIALITY

6/10 qualitative impact   moderate  medium-term · mixed evidence

Where AI matters: MA admin automation, claims ops, AVA clinical risk stratification/MLR

Claims auto-adjudication (<15% to >60% YTD) and ~60 bps adjusted SG&A improvement show real operating leverage, but management does not attribute adjudication to AI and cites automation only partly for SG&A; 30+ agentic use cases and MLR gains remain largely pre-mid-2026 foundation work with AI disclosure deferred.

Caveats: Agentic AI pipeline largely undeployed until unified data and workflow documentation (~mid-2026); Claims adjudication surge may reflect workflow/RPA more than disclosed AI; ~$40M FY2026 CapEx may offset part of SG&A savings via amortization; Competitors can replicate similar AI-driven cost curves, eroding differentiation

AI DISRUPTION / CANNIBALIZATION RISK  tailwind · 3/10

ALHC earns capitated MA premiums and risk-adjusted margins, not billable labor hours; GenAI mainly threatens parity on admin/MLR efficiency rather than automating away licensed plan operations, networks, Stars, or human-led Care Anywhere delivery that management explicitly keeps central.

OPTIONS / MARKET STRUCTURE

option liquidity: fair

ATM IV
—
TYPICAL BID-ASK
—
OPEN INTEREST
—

proxy inputs — dollar-ADV $71M · beta 1.27 · px $15.27

source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.

VERBATIM AI QUOTES
“just 12 months ago, our claims auto adjudication rate was less than 15%. Now our year-to-date auto adjudication rate is over 60%, and we expect to drive even higher claims automation as we progress throughout this year.”
— John E. Kao (CEO), Q1 FY2026
“we are also deploying contract management solutions that leverage AI to create a more dynamic contract management platform and taking the next leap forward in our AVA AI risk stratification models to create even greater precision in our clinical engagement efforts.”
— John E. Kao (CEO), Q1 FY2026
“We are continuing to invest in the scalability of our platform, including automation, AI-enabled workflows and enhancements to our clinical infrastructure, all of which position us to drive further efficiency and growth over time.”
— John E. Kao (CEO), Q1 FY2026
“we will likely have more transparency on the next call around how we are deploying AI. And just — I think the opportunities for us in terms of our clinical operations, our provider data, our stars, our MR, like every part of the company can benefit from that and we will continue to drive down the SG&A in particular and the MLR, I think. And so what we have had to do to maximize the benefit of AI and the tools that are available to us, which I think are just amazing is make sure we understand and validate all of the data. I think we have the best data in the industry, and we are going to get that even better. And I think our workflows, our end-to-end provider workflows, our end-to-end member workflows, our end-to-end Stars workflows, all of that is getting documented molecularly now so that we can apply the AI tools on top of that. And that is where the CapEx is going towards.”
— John E. Kao (CEO), Q1 FY2026
“Our SG&A discipline and scalability initiatives such as back-office automation supported outperformance in our operating cost ratio.”
— James M. Head (CFO), Q1 FY2026
“The data insights provided by our AIVA technology platform, combined with our Care Anywhere clinical model provided us with the visibility and control necessary to navigate a year of significant disruption, where we overcame the second phase of the V28 risk model, a redesign of the Part D program and broad utilization pressures across the Medicare Advantage industry.”
— John Kao (CEO), Q4 FY2025
“2026 will be a year of continuous improvement where we plan to make targeted investments across our clinical model, new market playbook and scalability initiatives, including investment in AI workflows to improve administrative efficiency.”
— John Kao (CEO), Q4 FY2025
“We're getting even tougher on ourselves internally from an operational perspective, from a clinical perspective, from an AI deployment perspective. We're just getting stronger to really get to the level of growth we think we can get to over the next 3 or 4 years.”
— John Kao (CEO), Q4 FY2025
“we also plan to reinvest a portion of the savings derived from improved operating efficiency towards further advancements in our clinical model, new market activities and technology infrastructure to prepare for scaling our business and the deployment of AI workflows in the future.”
— James Head (CFO), Q4 FY2025
“We've got 30-some-odd different potential use cases where we could deploy Agentic AI. Having the use cases is not our issue. What we're actually doing is to require 2 foundational actions be at a level where we're satisfied. And the first one is really as part of this kind of revalidation of everything. It starts with a unified data architecture. It starts with AVA. And we're just looking at everything. We're making sure all the data ingestion is as tight as we think it is. We're validating everything. We're not assuming anything, all of which is designed to ensure that we can scale and replicate without any abrasion.”
— John Kao (CEO), Q4 FY2025
“The second issue is what we're talking about internally, is just making sure the end-to-end workflows within each functional area is well documented and frankly, well understood... once I get those done, which we expect to have done midyear this year, you're going to see us start deploying these use cases for Agentic AI.”
— John Kao (CEO), Q4 FY2025
“we're kind of revisiting the initial stratification model within AVA. And I think there's going to be tools that we have... we talk about AVA and we're looking at using the new tools to make the stratification model even better for our Care Anywhere members of the 10% of the population we think that account for 78% of the spend.”
— John Kao (CEO), Q4 FY2025
“you're also going to see us have use cases around administrative improvements. I think member services is going to be one of the first ones, and I think there's going to be immediate savings there. I think in our financial reporting, I think you're going to -- we're going to be able to use AI and look at the raw data and be able to come up with actionable conclusions market by market.”
— John Kao (CEO), Q4 FY2025
“What we're probably not going to do is kind of lead the market in deploying Agentic AI in care delivery. We're going to still rely on our doctors and nurses to do that.”
— John Kao (CEO), Q4 FY2025
ANALYST QUESTIONS ON AI
Q (Q4 FY2025, Matthew Gillmor (KeyBanc)): maybe asking about AI investments. You mentioned some investments in the prepared remarks. I think last call, you also talked about AI within Care Anywhere and AVA. Just wanted to get a flavor for where some of the technology enhancements you have in flight, where they maybe be directed and how that may benefit the business over time?
A: John Kao: identified 30+ agentic AI use cases; described two foundational prerequisites not yet complete — (1) unified data architecture validated through AVA, and (2) molecular end-to-end workflow documentation across all functional areas — both expected done midyear 2026; then plans to deploy agentic AI beginning with member services ('immediate savings') and AI-driven financial reporting for market-by-market insights; revisiting AVA stratification model with new tools to improve precision on the 10% of members driving 78% of spend; explicitly ruled out leading in AI-driven care delivery.
Q (Q4 FY2025, John Ransom (Raymond James)): Just thinking about bending the trend with AVA, 1.0 was, I think, pop health 1.0 was CHF, COPD, type 2 diabetes. What's the -- if it's going to become more about bending the trend, what's kind of 2.0 in terms of deploying your assets to do that?
A: John Kao: AVA 2.0 involves more precise stratification models, more efficient clinician workforce management, focus on clinical outcome measures beyond utilization metrics, improved transitions-of-care and case-management programs, tighter integration with provider partners for medical management, and palliative programs — each representing incremental cost-curve opportunities. Also cited supplemental-benefit captives (dental, vision, transportation) as a complementary MLR lever once scale reaches ~300k members.
Q (Q1 FY2026, Ryan Daniels (William Blair)): Is that another strategy along with AI to kind of help the cost profile of the organization? [asked in context of deploying capital to bring ancillary/supplemental benefits in-house]
A: John Kao confirmed yes in principle, but focused his answer almost entirely on the supplemental-benefit captive strategy (dental PPO/HMO, vision, transportation) rather than on AI specifically. AI was acknowledged in the analyst's framing but not addressed as a distinct cost-reduction mechanism in the response.